MA53982A - Protéines hétérodimères fusionnées à un fragment fc - Google Patents

Protéines hétérodimères fusionnées à un fragment fc

Info

Publication number
MA53982A
MA53982A MA053982A MA53982A MA53982A MA 53982 A MA53982 A MA 53982A MA 053982 A MA053982 A MA 053982A MA 53982 A MA53982 A MA 53982A MA 53982 A MA53982 A MA 53982A
Authority
MA
Morocco
Prior art keywords
fragment
proteins fused
heterodimer proteins
heterodimer
fused
Prior art date
Application number
MA053982A
Other languages
English (en)
Inventor
Ann F Cheung
Jean-Marie Cuillerot
Asya Grinberg
Eva Gutierrez
William Haney
Nicolai Wagtmann
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MA53982A publication Critical patent/MA53982A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
MA053982A 2018-10-23 2019-10-23 Protéines hétérodimères fusionnées à un fragment fc MA53982A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862749489P 2018-10-23 2018-10-23
US201862781898P 2018-12-19 2018-12-19
US201962788499P 2019-01-04 2019-01-04
US201962827347P 2019-04-01 2019-04-01
US201962895889P 2019-09-04 2019-09-04

Publications (1)

Publication Number Publication Date
MA53982A true MA53982A (fr) 2022-01-26

Family

ID=68583501

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053982A MA53982A (fr) 2018-10-23 2019-10-23 Protéines hétérodimères fusionnées à un fragment fc

Country Status (17)

Country Link
US (2) US20220119533A1 (fr)
EP (1) EP3870598A1 (fr)
JP (1) JP2022505871A (fr)
KR (1) KR20210080460A (fr)
CN (1) CN113286808A (fr)
AU (1) AU2019366956A1 (fr)
BR (1) BR112021007175A2 (fr)
CA (1) CA3117212A1 (fr)
CL (2) CL2021001058A1 (fr)
CO (1) CO2021006474A2 (fr)
IL (1) IL281954A (fr)
MA (1) MA53982A (fr)
MX (1) MX2021004711A (fr)
PE (1) PE20211279A1 (fr)
SG (1) SG11202104136YA (fr)
TW (1) TW202033547A (fr)
WO (1) WO2020086758A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016104657A1 (fr) * 2014-12-26 2016-06-30 橋本 正 Agent thérapeutique contre le cancer
CN110267977A (zh) 2016-08-10 2019-09-20 亚洲大学校产学协力团 细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CN112040971A (zh) * 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
CA3098374A1 (fr) 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Anticorps anti-tl1a optimises
EP3818083A2 (fr) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
CN113286812A (zh) 2018-09-27 2021-08-20 西里欧发展公司 掩蔽型细胞因子多肽
AU2019355971A1 (en) 2018-10-03 2021-05-06 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CN113286808A (zh) 2018-10-23 2021-08-20 蜻蜓疗法股份有限公司 异二聚体Fc融合蛋白
CA3151574A1 (fr) * 2019-09-27 2021-04-01 Dhan Sidhartha CHAND Proteines heterodimeres
AU2020358979A1 (en) 2019-10-03 2022-04-21 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
EP4048309A4 (fr) 2019-10-24 2024-02-21 Prometheus Biosciences Inc Anticorps humanisés contre le ligand 1a de type tnf (tl1a) et leurs utilisations
IL297225A (en) 2020-04-10 2022-12-01 Cytomx Therapeutics Inc Activatable cytokine constructs and related compositions and methods
JP2023522972A (ja) * 2020-04-22 2023-06-01 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程
CA3174236A1 (fr) * 2020-05-22 2021-11-25 Alwin REITER Proteines de fusion d'ace2 et leurs utilisations
EP4204091A2 (fr) * 2020-10-29 2023-07-05 Formycon AG Protéines de fusion ace2 et leurs utilisations
US11667687B2 (en) 2021-03-16 2023-06-06 Cytomx Therapeutics, Inc. Masked activatable interferon constructs
WO2023001884A1 (fr) * 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Anticorps de domaine fc hétérodimères
CN115925982A (zh) * 2021-08-24 2023-04-07 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
WO2023070056A2 (fr) * 2021-10-20 2023-04-27 Synthekine, Inc. Cytokines fc hétérodimères et leurs utilisations
WO2023086772A1 (fr) 2021-11-12 2023-05-19 Xencor, Inc. Anticorps bispécifiques se liant à b7h3 et à nkg2d

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
GB9022040D0 (en) 1990-10-10 1990-11-21 Biopharm Ltd Platelet adhesion inhibitor
US5851794A (en) 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1993021226A1 (fr) 1992-04-10 1993-10-28 The General Hospital Corporation Proteine de matrice de cartilage et procedes d'utilisation
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
DE69734601T2 (de) 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
WO2000021989A1 (fr) 1998-10-09 2000-04-20 Medimmune, Inc. Proteines dbp a et b liant la decorine et gene codant pour elles
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6566489B1 (en) 1999-03-15 2003-05-20 The General Hospital Corporation Syndecan-4 binding protein (S4BP) and uses thereof
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6908994B1 (en) 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
AU5495500A (en) 1999-06-16 2001-01-02 The Texas A & M University System Decorin binding protein essential peptides and methods of use
AU5622800A (en) 1999-06-18 2001-01-09 Med Immune, Inc. Combined decorin binding protein and outer surface protein compositions and methods of use
IL150198A0 (en) 1999-12-15 2002-12-01 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
US6517838B1 (en) 2000-06-16 2003-02-11 The Texas A&M University System Decorin binding protein essential peptides and methods of use
AU2001292943A1 (en) 2000-09-21 2002-04-02 The Brigham And Women's Hospital, Inc. Prevention and treatment of streptococcal and staphylococcal infection
AU2002315857B2 (en) 2001-06-22 2007-07-26 Kaisha, Chugai Seiyaku Kabushiki Cell proliferation inhibitors containing anti-glypican 3 antibody
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
GB0406415D0 (en) 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
EP1752767B1 (fr) 2004-05-20 2011-07-13 Wako Pure Chemical Industries, Ltd. Procédé de dosage de l'acide hyaluronique en utilisant une protéine liant l'acide hyaluronique
EP1761782A2 (fr) 2004-06-18 2007-03-14 Roche Diagnostics GmbH Utilisation d'une proteine cbp2 en tant que marqueur pour un cancer colorectal
KR101413402B1 (ko) 2004-07-09 2014-06-27 츄가이 세이야꾸 가부시키가이샤 항 글리피칸 3 항체
WO2006023382A2 (fr) 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagene vi et cancer
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
CA2610791C (fr) 2005-06-08 2015-12-01 Cangene Corporation Peptides de liaison a l'acide hyaluronique pour ameliorer les defenses de l'organisme hote contre les bacteries pathogenes
NZ564592A (en) 2005-07-01 2011-11-25 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
EP1864996A1 (fr) 2006-06-06 2007-12-12 Helmholtz-Zentrum für Infektionsforschung GmbH Peptide associé de la fievre rhumatismale et son utilisation comme marquer diagnostique.
HU0600578D0 (en) 2006-07-13 2006-09-28 Szilak Labor Bioinformatikai E Nuclear protein transport
US8163498B2 (en) 2006-08-08 2012-04-24 Seikagaku Corporation Method for determination of molecular weight of hyaluronic acid
US8465732B2 (en) 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
PL2178921T3 (pl) 2007-07-17 2016-06-30 Squibb & Sons Llc Monoklonalne przeciwciała przeciwko glipikanowi-3
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2270509B1 (fr) 2008-03-17 2014-01-15 University of Miyazaki Procédé de détection d'une cellule de cancer du foie à l'aide d'un anticorps anti-glypicane-3
US20090297479A1 (en) 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
CA2720368C (fr) 2008-04-02 2017-08-22 Macrogenics, Inc. Anticorps specifiques de her2/neu et procedes d'utilisation de ceux-ci
ES2399584T3 (es) 2008-04-15 2013-04-02 Wako Pure Chemical Industries, Ltd. Nueva proteína capaz de unirse al ácido hialurónico y procedimiento para medir el ácido hialurónico usando la misma
JP2012503203A (ja) 2008-09-19 2012-02-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体
GB0818273D0 (en) 2008-10-06 2008-11-12 Cambridge Entpr Ltd Modulation of cellular activity and differentiation
KR101105428B1 (ko) 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
AU2010233994A1 (en) 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
US20120100106A1 (en) 2009-05-04 2012-04-26 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
KR101586128B1 (ko) 2010-08-24 2016-01-15 에프. 호프만-라 로슈 아게 디술피드 안정화 ― Ｆｖ 단편을 포함하는 이중특이적 항체
WO2012032080A1 (fr) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Fc humain stabilisé
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
WO2012058768A1 (fr) 2010-11-05 2012-05-10 Zymeworks Inc. Conception d'anticorps hétérodimérique stable ayant des mutations dans le domaine fc
JP6100694B2 (ja) 2010-11-15 2017-03-22 ピエリス ファーマシューティカルズ ゲーエムベーハー グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質
CA2819530C (fr) * 2010-11-30 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique induisant une cytotoxicite
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
TWI666027B (zh) * 2011-02-10 2019-07-21 羅齊克雷雅公司 突變介白素-２多肽
EP2691417B1 (fr) 2011-03-29 2018-08-01 Roche Glycart AG Variants de fc d'anticorps
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
SG10201604171WA (en) 2011-05-24 2016-07-28 Symic Ip Llc Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
CA2850575C (fr) * 2011-10-11 2020-12-15 Universitat Zurich Prorektorat Mnw Combinaison medicamenteuse comprenant de l'il-12 et un agent de blocage de molecules inhibitrices des lymphocytes t pour une therapie anti-tumorale
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
EP2804586A4 (fr) 2012-01-19 2016-03-16 Univ Johns Hopkins Biomatériaux comprenant des peptides se liant à l'acide hyaluronique et des molécules biopolymères bifonctionnelles pour des applications de rétention d'acide hyaluronique et d'ingénierie tissulaire
JP6393255B2 (ja) 2012-04-20 2018-09-19 メルス ナムローゼ フェンノートシャップ ヘテロ二量体のＩｇＧ様分子を生産する方法、ヘテロ二量体のＩｇＧ様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物
WO2013163766A1 (fr) 2012-05-04 2013-11-07 Cangene Corporation Compositions antimicrobiennes comprenant un peptide de liaison à l'acide hyaluronique et un antibiotique β-lactame
WO2013174783A1 (fr) 2012-05-23 2013-11-28 Pieris Ag Mutéines de lipocaline avec affinité de liaison pour le glypican-3 (gpc-3) et utilisation de mutéines de lipocaline pour la délivrance spécifique de la cible aux cellules exprimant le gpc-3
WO2013181543A1 (fr) 2012-06-01 2013-12-05 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps monoclonaux à affinité élevée contre le glypicane 3 et utilisation de ceux-ci
SG11201408530YA (en) 2012-08-02 2015-03-30 Hoffmann La Roche Method for producing monomeric and multimeric molecules and uses thereof
BR112015002263A2 (pt) 2012-08-02 2017-12-12 Hoffmann La Roche polipeptídeo de fusão, polipeptídeo de fusão dimérico, método para a produção de um receptor fc solúvel, uso de um polipeptídeo de fusão imobilizado e composição farmacêutica
MY175687A (en) 2012-08-07 2020-07-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
AU2013352812B2 (en) 2012-11-27 2019-06-20 Ajou University Industry-Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
EP2970435B1 (fr) 2013-03-15 2020-08-12 Eli Lilly and Company Procédés de production de fab et d'anticorps bispécifiques
SI2970422T1 (en) * 2013-03-15 2018-07-31 F. Hoffmann-La Roche Ag IL-22 polypeptides and IL-22-Fc fusion proteins and procedures for use
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2970486B1 (fr) 2013-03-15 2018-05-16 Xencor, Inc. Modulation de cellules t avec des anticorps bispecifiques et des fusions fc
MX2015015060A (es) 2013-04-29 2016-02-25 Hoffmann La Roche Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
WO2014194100A1 (fr) 2013-05-29 2014-12-04 The Regents Of The University Of California Fusions anti-cspg4 et interféron utilisables en vue du traitement de tumeurs malignes
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
US20160032007A1 (en) 2014-04-28 2016-02-04 Duke University Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
RU2727012C2 (ru) 2014-05-06 2020-07-17 Дженентек, Инк. Получение гетеромультимерных белков с использованием клеток млекопитающих
EP3161002A1 (fr) 2014-06-27 2017-05-03 Innate Pharma Protéines de liaison nkp46 multispécifiques
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MX2017005150A (es) 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
RS59340B1 (sr) 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
CA2967350C (fr) 2014-11-12 2021-11-23 The General Hospital Corporation Anticorps anti-proteoglycane de chondroitine-sulfate 4 et utilisations de ceux-ci
WO2016150884A1 (fr) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulateurs de syndécane 2 et leurs utilisations
US10881711B2 (en) 2015-04-06 2021-01-05 The General Hospital Corporation Anti-CSPG4 reagents and methods of treating cancer
US11370845B2 (en) 2015-06-24 2022-06-28 Keio University Anti-glypican-1-immunizing antigen receptor
NZ738950A (en) * 2015-08-07 2023-03-31 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
US10995317B2 (en) 2015-09-14 2021-05-04 Regents Of The University Of Minnesota NK cells exhibiting an adaptive phenotype and methods for preparing and for using
CN108884147B (zh) 2015-09-23 2024-02-27 百时美施贵宝公司 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
BR112018006811A2 (pt) 2015-10-06 2018-10-16 Univ Minnesota compostos terapêuticos e métodos
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
JP6983824B2 (ja) 2016-07-04 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規抗体フォーマット
EP3494135A1 (fr) 2016-08-02 2019-06-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Anticorps monoclonaux ciblant le glypican-2 (gpc2) et leur utilisation
CN110267977A (zh) 2016-08-10 2019-09-20 亚洲大学校产学协力团 细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
WO2018030806A1 (fr) * 2016-08-10 2018-02-15 아주대학교산학협력단 Cytokine fusionnée à un hétérodimère fc d'immunoglobuline et composition pharmaceutique la contenant
PE20191033A1 (es) * 2016-10-14 2019-08-05 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
CN110831634A (zh) 2017-03-08 2020-02-21 密歇根大学董事会 磷脂酰肌醇蛋白聚糖-3肽试剂和方法
CA3056837A1 (fr) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Recepteurs de liaison a l'antigene ameliores
WO2018199176A1 (fr) 2017-04-26 2018-11-01 Mitsubishi Tanabe Pharma Corporation Agents de liaison à syndécane-1 (cd138) et leurs utilisations
WO2018199318A1 (fr) 2017-04-28 2018-11-01 国立大学法人高知大学 Anticorps anti-gpc-1
JP2019014449A (ja) 2017-07-10 2019-01-31 トヨタ自動車株式会社 車両用動力伝達装置
RU2021110369A (ru) 2017-09-07 2021-06-01 Драгонфлай Терапьютикс, Инк. Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
RU2020113713A (ru) * 2017-09-21 2021-10-21 Мерк Патент Гмбх Слитый белок, содержащий молекулу fgf-18
JP7387611B2 (ja) * 2017-09-22 2023-11-28 ウーシー バイオロジクス アイルランド リミテッド 新規二重特異性ポリペプチド複合体
CA3078157A1 (fr) 2017-10-20 2019-04-25 F.Hoffmann-La Roche Ag Procede de generation d'anticorps multispecifiques a partir d'anticorps monospecifiques
CN112040971A (zh) 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
DE102018208278A1 (de) 2018-05-25 2019-11-28 Robert Bosch Gmbh Betriebsassistenzverfahren, Steuereinheit, Betriebsassistenzsystem und Arbeitsvorrichtung
KR20210042326A (ko) * 2018-07-11 2021-04-19 모멘타 파머슈티컬스 인코포레이티드 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
CN113286808A (zh) 2018-10-23 2021-08-20 蜻蜓疗法股份有限公司 异二聚体Fc融合蛋白

Also Published As

Publication number Publication date
BR112021007175A2 (pt) 2021-08-10
WO2020086758A1 (fr) 2020-04-30
WO2020086758A8 (fr) 2021-05-06
US20230033425A1 (en) 2023-02-02
PE20211279A1 (es) 2021-07-19
US11787864B2 (en) 2023-10-17
US20220119533A1 (en) 2022-04-21
EP3870598A1 (fr) 2021-09-01
TW202033547A (zh) 2020-09-16
CO2021006474A2 (es) 2021-06-10
CA3117212A1 (fr) 2020-04-30
CN113286808A (zh) 2021-08-20
AU2019366956A1 (en) 2021-05-20
JP2022505871A (ja) 2022-01-14
IL281954A (en) 2021-05-31
SG11202104136YA (en) 2021-05-28
CL2021001058A1 (es) 2021-11-12
KR20210080460A (ko) 2021-06-30
MX2021004711A (es) 2021-07-02
CL2022000900A1 (es) 2023-01-20

Similar Documents

Publication Publication Date Title
MA53982A (fr) Protéines hétérodimères fusionnées à un fragment fc
MA46534A (fr) Protéines de fusion fc hétérodimères il15/il15r
MA51291A (fr) Protéines de fusion il-2 fc modifiées
MA46299A (fr) Molécule de polypeptide à double spécificité améliorée
MA43019A (fr) Anticorps anti-humain cd19 à affinité élevée
MA53616A (fr) Protéines bispécifiques modifiées
MA53822A (fr) Protéines de fusion fc hétérodimères d'il -12
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
DK3334457T3 (da) Humaniserede anti-CCR7-receptorantistoffer
DK3584189T3 (da) Fastgjort bindeledslåg
DK3833662T3 (da) Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
KR20220035471A (ko) 면역치료법을 위한 융합 폴리펩티드
DK3743337T3 (da) Vilkårlig kasselukker
DK3199179T3 (da) Formulering af rekombinant fusionsprotein
DK3325011T3 (da) Fusionsproteiner af humane proteinfragmenter til fremstilling af ordnede multimeriserede immunoglobulin Fc-sammensætninger med forstærket komplementbinding
MA53498A (fr) Production de protéines recombinantes
MA43773A (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
MA50174A (fr) Formules de protéines de fusion vegfr-fc
DK3584654T3 (da) Hierarkisk fordelt ledger
DK3728288T3 (da) Fremgangsmåder til forbedret fjernelse af urenheder under protein a-kromatografi
DK3591122T3 (da) Hurtigskifter
MA45695A (fr) Protéines de liaison à un antigène qui se lient à cxcr3
DK3833786T3 (da) Rekombinant nucleinsyrekonstrukt
MA48777A (fr) Nouvelles protéines de liaison à un antigène
FR3082330B1 (fr) Cybersecurite aeronautique